Posted by Michael Wonder on 22 Dec 2020
Shionogi’s novel antibiotic, Fetcroja (cefiderocol), has been selected by UK’S NICE/NHSE&I as part of an antimicrobial subscription style reimbursement model
21 December 2020 - NICE and the National Health Service England and Improvement have recognised the potential of Shionogi’s innovative antibiotic, cefiderocol, and selected it for inclusion in this pilot reimbursement model which ‘de-links’ payment from volume of use.
Shionogi today announce that NICE and NHSE&I have selected its innovative antibiotic, cefiderocol, for inclusion in a pilot subscription reimbursement model in the UK which ‘de-links’ payment from volume of use, thereby recognising its potential in treating multi-drug resistant Gram-negative bacterial infections and its benefits to society and healthcare systems.
This scheme is called the UK Project for developing and testing an innovative model for the evaluation and purchase of antimicrobials. Pull incentives such as this are an important step to help bring urgently needed new antibiotics to market.
